Cryoprecipitate |

Cryoprecipitate

Saurav Suman Post graduate Resident, Department of Medicine, LHMC

Cryoprecipitate is a portion of plasma rich in clotting factors which is mainly used to prevent or control bleeding in people whose own blood does not clot properly.

PREPRATION AND COMPONENTS: Fresh Frozen Plasma (FFP) is thawed between 1 and 6°C and subsequently centrifuged. The insoluble precipitate is then resuspended in approximately 15 mL of plasma and refrozen at -18°C. This process creates one unit of Cryoprecipitate. It contains cold insoluble plasma proteins, Fibrinogen, Factor viii, Factor xiii, vWF, Fibronectin.

DOSE AND INFUSION RATE: Cryoprecipitate can be provided as single units or as “pools” containing multiple units. An appropriate dose of cryoprecipitate is between 5 and 10 equivalent units (one to two five-unit “pools”). Thus, a typical dose is provided in a volume of 50 to 200 ml.

Infusion rate — cryoprecipitate can be infused as rapidly as tolerated (generally 2 to 5 ml per minute in a patient without hypervolemia).

INDICATIONS:

Cryoprecipitate is indicated for the treatment of acquired fibrinogen deficiency or dysfibrinogenaemia due to criticial bleeding, an invasive procedure, trauma or disseminated intravascular coagulation (DIC).

Cryoprecipitate should not be used for patients with Hemophilia A (Factor VIII deficiency) unless other recombinant and/or virally inactivated factor VIII preparations are not available.